Relmada Therapeutics (RLMD) Share-based Compensation (2014 - 2026)
Relmada Therapeutics (RLMD) reported Share-based Compensation of $956186.0 for Q1 2026, down 73.24% year-over-year from $3.6 million in Q1 2025, and down 59.67% on a QoQ basis from $2.4 million in Q4 2025.
Relmada Therapeutics (RLMD) has 13 years of Share-based Compensation data on file, last reported at $956186.0 in Q1 2026.
- Quarterly Share-based Compensation fell 73.24% year-over-year to $956186.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (down 55.66% YoY) and the FY2025 annual result came in at $13.9 million, down 53.93% from the prior year.
- Share-based Compensation retreated to $956186.0 in Q1 2026 per RLMD's latest filing, from $2.4 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $12.3 million in Q2 2022 and bottomed at $956186.0 in Q1 2026.
- The 5-year median for Share-based Compensation is $8.3 million (2024), against an average of $7.8 million.
- The widest annual swing landed in 2022, when Share-based Compensation soared 103.9%; it then tumbled 73.24% in 2026.
- Tracing RLMD's Share-based Compensation over 5 years: stood at $11.6 million in 2022, then declined by 14.9% to $9.9 million in 2023, then sank by 32.02% to $6.7 million in 2024, then slumped by 64.75% to $2.4 million in 2025, then sank by 59.67% to $956186.0 in 2026.
- Per Business Quant, the three latest RLMD Share-based Compensation figures stand at $956186.0 (Q1 2026), $2.4 million (Q4 2025), and $3.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | 956,186.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 956,186.00 |
| Mar 31, 2026 | 956,186.00 |
| Dec 31, 2025 | 2.37 Mn |
| Dec 31, 2025 | 2.37 Mn |
| Sep 30, 2025 | 3.61 Mn |
| Sep 30, 2025 | 3.61 Mn |
| Jun 30, 2025 | 4.35 Mn |
| Jun 30, 2025 | 4.35 Mn |
| Mar 31, 2025 | 3.57 Mn |
| Mar 31, 2025 | 3.57 Mn |
| Dec 31, 2024 | 6.73 Mn |
| Dec 31, 2024 | 6.73 Mn |
| Sep 30, 2024 | 7.95 Mn |
| Sep 30, 2024 | 7.95 Mn |
| Jun 30, 2024 | 7.21 Mn |
| Jun 30, 2024 | 7.21 Mn |
| Mar 31, 2024 | 8.30 Mn |
| Mar 31, 2024 | 8.30 Mn |
| Dec 31, 2023 | 9.89 Mn |
| Dec 31, 2023 | 9.89 Mn |
| Sep 30, 2023 | 11.39 Mn |
| Sep 30, 2023 | 11.39 Mn |
| Jun 30, 2023 | 11.17 Mn |
| Jun 30, 2023 | 11.17 Mn |
| Mar 31, 2023 | 11.35 Mn |
| Mar 31, 2023 | 11.35 Mn |
| Dec 31, 2022 | 11.63 Mn |
| Dec 31, 2022 | 11.63 Mn |
| Sep 30, 2022 | 8.34 Mn |
| Sep 30, 2022 | 8.34 Mn |
| Jun 30, 2022 | 12.29 Mn |
| Jun 30, 2022 | 12.29 Mn |
| Mar 31, 2022 | 11.93 Mn |
| Mar 31, 2022 | 11.93 Mn |
| Dec 31, 2021 | 18.36 Mn |
| Dec 31, 2021 | 18.36 Mn |
| Sep 30, 2021 | 8.01 Mn |
| Sep 30, 2021 | 8.01 Mn |
| Jun 30, 2021 | 8.27 Mn |
| Jun 30, 2021 | 8.27 Mn |
| Mar 31, 2021 | 5.85 Mn |
| Mar 31, 2021 | 5.85 Mn |
| Dec 31, 2020 | 3.19 Mn |
| Dec 31, 2020 | 3.19 Mn |
| Sep 30, 2020 | 5.24 Mn |
| Sep 30, 2020 | 5.24 Mn |
| Jun 30, 2020 | 7.30 Mn |
| Jun 30, 2020 | 7.30 Mn |
| Mar 31, 2020 | 5.04 Mn |
| Mar 31, 2020 | 5.04 Mn |
| Dec 31, 2019 | 2.37 Mn |
| Dec 31, 2019 | 2.37 Mn |
| Sep 30, 2019 | 757,716.00 |
| Sep 30, 2019 | 757,716.00 |
| Jun 30, 2019 | 798,200.00 |
| Jun 30, 2019 | 798,200.00 |
| Mar 31, 2019 | 394,692.00 |
| Mar 31, 2019 | 394,692.00 |
| Dec 31, 2018 | -1.14 Mn |
| Dec 31, 2018 | -1.14 Mn |
| Sep 30, 2018 | 152,800.00 |
| Sep 30, 2018 | 152,800.00 |
| Mar 31, 2018 | 162,273.00 |
| Mar 31, 2018 | 162,273.00 |
| Dec 31, 2017 | 134,000.00 |
| Dec 31, 2017 | 134,000.00 |
| Sep 30, 2017 | 68,900.00 |
| Sep 30, 2017 | 68,900.00 |
| Jun 30, 2017 | 291,852.00 |
| Jun 30, 2017 | 291,852.00 |
| Mar 31, 2017 | 108,576.00 |
| Mar 31, 2017 | 108,576.00 |
| Dec 31, 2016 | 131,960.00 |
| Dec 31, 2016 | 131,960.00 |
| Sep 30, 2016 | 172,064.00 |
| Sep 30, 2016 | 172,064.00 |
| Jun 30, 2016 | 154,819.00 |
| Jun 30, 2016 | 154,819.00 |
| Mar 31, 2016 | 276,543.00 |
| Mar 31, 2016 | 276,543.00 |
| Dec 31, 2015 | 287,710.00 |
| Dec 31, 2015 | 287,710.00 |
| Sep 30, 2015 | 283,504.00 |
| Sep 30, 2015 | 283,504.00 |
| Jun 30, 2015 | 196,876.00 |
| Jun 30, 2015 | 196,876.00 |
| Mar 31, 2015 | 243,810.00 |
| Mar 31, 2015 | 243,810.00 |
| Dec 31, 2014 | 198,276.00 |
| Dec 31, 2014 | 198,276.00 |
| Sep 30, 2014 | 157,990.00 |
| Sep 30, 2014 | 157,990.00 |
| Jun 30, 2014 | 10.32 Mn |
| Jun 30, 2014 | 10.32 Mn |
| Mar 31, 2014 | 447,780.00 |
| Mar 31, 2014 | 447,780.00 |